Role of Transient Elastography in Early Detection of HCC in Cirrhotic Patients
|
|
- Jessie Adams
- 5 years ago
- Views:
Transcription
1 159 Role of Transient Elastography in Early Detection of HCC in Cirrhotic Patients Abdel Ghani Atef Badran 1, Naglaa El-Tokhy Ramadan El-Tokhy 2, Seham Mohamad Seif 3 and Hossam Amin Baioumy 2 1 Liver and GIT center,damas, Meet Ghamr,Dakahlia,Egypt 2 GIT, Hepatology and infectious DiseasesDepartment, Faculty of Medicine, Benha University 3 Internal Medicine (GIT and Hepatology)Department, Faculty of Medicine, Mansoura University Corresponding Author Abdel-Ghani Atef Badran Mobile: E mail: prof_abdo1985@yaho o.com Key words: Hepatocellular carcinoma; transient elastography; liver stiffness Background and study aim: Hepatocellular carcinoma (HCC) is common primary malignancy of the liver and one of the most frequent causes of death in patients with liver cirrhosis. Nowadays, liver stiffness measured noninvasively by transient elastography has been reported to be well correlated with histologically assessed liver fibrosis stage. The degree of liver fibrosis is the strongest indicator of risk for HCC development, that s why liver stiffness measured by transient elastography is helpful in demarcating patients at a high risk for HCC, who need frequent check-up by imaging examinations.the aim of this study was to study the role of ultrasound elastography (FibroScan) in early detection of hepatocellular carcinoma in cirrhotic patients as well as verifying whether ultrasound elastography (Fibro-Scan), could be used as a tool for identifying cirrhotic patients who are at high risk of developing HCC. Patients and Methods: This study included 100 patients; 50 with HCC and 50 cirrhotics without evidence of HCC. For all groups, clinical data and image findings were studied. Tumour characteristics were assessed including size, number and site. Tumor staging was done using Okuda, CLIP, VISUM and Tokyo staging systems. Transient elastography was done for all patients and the results were expressed in kilopascal. Results: Liver stiffness was significantly higher in HCC patients compared to cirrhotic patients. The sensitivity and specificity in diagnosis of HCC were 72% and 84% respectively at cut-off of 30.4 kpa with 91.1% accuracy. Fibroscan has a positive significant correlation with tumour size (P<0.001), Child Pugh (P<0.001), Okuda classification (P<0.001), CLIP staging (P<0.001) and Tokyo classification (P<0.001) among HCC patients. It was found that likelihood of HCC risk was correlated with increase of liver stiffness. At liver stiffness of kpa the probability of HCC is 91% so, these patients should undergo close follow up. Patients with stiffness 30 kpa had HCC. Conclusion: Fibroscan could be used for early detection of HCC in cirrhotic patients and determining the patients who are at high risk for developing HCC. INTRODUCTION Hepatocellular carcinoma is common primary malignancy of the liver and one of the most frequent cause of death in patients with liver cirrhosis [1]. It is one of the most challenging tumors with high incidence, prevalence and mortality rates in Egypt [2]. Nowadays, liver stiffness measured noninvasively by transient elastography has been reported to be well correlated with histologically assessed liver fibrosis stage [3]. The degree of liver fibrosis is the strongest indicator of risk for HCC development, that s why liver stiffness measured by transient elastography is helpful in demarcating patients at a high risk for HCC, who need frequent check-up by imaging examinations [4]. This work aimed to study the role of ultrasound elastography (FibroScan) in Early Detection of Hepatocellular Carcinoma in Cirrhotic Patients as well as verifying whether ultrasound elastography (FibroScan), could be used as a tool for identifying cirrhotic patients who are at high risk of developing HCC. Badran et al., Afro-Egypt J Infect Endem Dis 2017; 7(3):
2 160 PATIENTS AND METHODS This study was approved by the ethics and research committee of Benha faculty of medicine, Benha University, Egypt. and all patients included in this study had the procedure thoroughly explained to them. All patients included in this study had the procedure thoroughly explained to them. This study was conducted on 100 patients with cirrhosis of both sexes who were attending Shebin Elkom Fever Hospital, Menofyia Governorate in the period from October 2014 to November The studied patients were classified into : Group I which included 50 patients with Cirrhosis and HCC diagnosed by ultrasound examination and confirmed by triphasic computed tomography. And Group II which included 50 patients with Cirrhosis and without evidence of HCC diagnosed by clinical, laboratory and ultrasound examination [5]. Patients with cirrhosis and Patients with HCC within Milan Criteria were included in this study. While patients with morbid obesity, ascites, hepatic metastatic lesions and patients with HCC beyond Milan criteria were excluded from this study. HCC was diagnosed by abdominal US and confirmed by triphasic CT scan. AFP was assayed by an enzyme immunoassay (EIA) Kit (Roche Mannheim, Germany). The clinical/pathological data of the patients were recorded, including age, sex, viral infections [Hepatitis C Virus (HCV) and Hepatitis B Virus (HBV)], alcohol intakes, biochemical liver function test results, and AFP levels. Severity of liver disease was assessed by modified Child-Pugh score [17] and MELD (model for end stage liver disease) score [18] and the updated MELD (umeld) score [19]. Tumor characteristics were detected by abdominal US with or without CT scan (including tumor size, number, site, halo sign and neovascularization). Tumor staging was done using Okuda [6], The Cancer of the Liver Italian Program (CLIP) [7], VISUM (Vienna survival model for HCC) [8], Tokyo [9] staging systems and Barcelona Clinical Liver Cancer Staging (BCLC Staging System) [10]. Blood sampling and biochemical assays Fasting venous blood samples (5 ml) were collected by trained laboratory technicians. A portion of blood was allowed to clot and then centrifuged at 3500g for 5 min to separate the serum used for assessment of aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, direct bilirubin, albumin, creatinine and glucose concentrations were assayed using Beckman CX4 chemistry analyzer (NY, USA, supplied by the Eastern Co. For Eng. & Trade- Giza, Egypt). Viral infection status (HCV Ab and HBsAg) were measured using Abbott, Axyam (USA, Supplied by Al kamal company). Serum AFP level was determined using an enzymelinked binding protein assay kit. All assays were performed in duplicate according to the manufacturer's instructions. Specific examination Liver stiffness was measured for patients using the transient elastogrpahy machine "Fibroscan" manufactured by Echosens. Results were expressed in kilo Pascals (kpa) and 10 validated measurements were recorded for each patient. Statistical analysis The statistical analysis was conducted using STATA/SE version 11.2 for Windows (STATA corporation, College Station, Texas). The collected data were summarized in terms of mean± Standard Deviation (SD) and range for quantitative data and frequency and percentage for qualitative data. Comparisons between the different study groups were carried out using the Chi-square test (χ2) and Fisher Exact test (FET) to compare proportions as appropriate. The Student t-test (t) was used to detect difference in the mean between two parametric data, while the Mann-Whitney test (z) was used to compare two non-parametric data. Receiver Operating Characteristics (ROC) analysis was carried out to evaluate the diagnostic performance of stiffness for HCC screening among cirrhotic patients. The best cutoff point and the corresponding sensitivity and specificity, Positive Predictive Value (PPV), Negative Predictive Value (NPV) and Area under the Curve (AUC) were estimated. Likelihood of presence of HCC is conducted using Stratum Specific Likelihood Ratio (SSLR). The significance level was set at P<0.05. A P value <0.001 was considered highly significant (HS) while a P value >0.05 was considered nonsignificant. The Pearson and Spearman correlation coefficient was used to test for the correlation between stiffness and different variables. RESULTS The demographic features and characteristics of the (two patients groups) were summarized in Table (1). A total of 100 adults, which included Badran et al., Afro-Egypt J Infect Endem Dis 2017; 7(3):
3 patients with HCC and 50 patients with liver cirrhosis and without evidence of HCC. In the current study, patients with HCC had a mean age of 53.5 years with a range between years old, while cirrhotic non-hcc patients are younger with a mean age of 51.3 years and ranging between years old. Also HCC commonly presented in males (84%) more than females (16%). 58% of HCC cases were from urban areas. Most of HCC cases were farmers (76%) while (24%) only were non-farmers. HCC was common in smokers than non-smokers. Regarding HCC etiology, the results showed that the frequency of HBV positivity had no statistically significant difference between the studied patients. It was not detected in HCC or Non-HCC cases HCV was present all cases with no statistically significant difference between the two groups. The liver functions in cirrhosis assessed by Child Pugh classification among the studied patients showed that 16% of HCC cases were Child A, while 20% of HCC cases were Child B and 64% were Child C with no statistical significant difference between the two groups. There was no statistically significant difference among the two groups as regards the severity of liver disease assessed by MELD scores (Table 1). Tumor imaging characteristics of HCC patients were illustrated in (Table 2). Abdominal CT showed that Cirrhosis was present in 100% of cases with HCC, most of cases had splenomegaly (94%). PVT was found in 14% of patients. Focal lesions by CT tended to be single, more in Right lobe, 3cm in diameter. Only 10% of patients had enlarged lymph nodes. As regard Okuda staging, most of HCC cases were in the late stage; stage III (46%), followed by stage II (38%) then stage I (16%). Concerning CLIP staging, most of HCC cases were presented at the intermediate stage II (62%) comparing to the patients presented at the early stage (10%) and the advanced stage (28%) respectively. According VISUM staging most of HCC cases (68%) were stage I. According to Tokyo staging, most of HCC patients were presented at advanced stage (58%) comparing to the patients presented at early stage (42%). As regards AFP levels, the data showed that AFP values were significantly different between HCC cases and cirrhotics (p=0.001). In this study, liver stiffness was assessed using transient elastography (TE) and the measurements were expressed in Kilopascal. Liver stiffness and Inter Quartile Range measured by Fibroscan were significantly higher in HCC group (P=0.001). But, there was no statistical significant difference between the groups as regards the success rate (P= 0.052). (Table 3) and Figure (1). In the receiver operating curve (ROC) (Table 4), Figure (2), the area under curve (AUC) was 91.18% when we use 30.4 kpa as a cut off point with sensitivity of 72%, specificity of 84%, positive predictive value of 81.82% and Negative predictive value of 75 %. It was found that likelihood of HCC risk was correlated with increase of liver stiffness. At liver stiffness of <25 kpa, the probability of HCC presence was about 72%,while stiffness of kpa has a probability of 91% so, these patients should undergo close follow up. Patients with stiffness 30 kpa had HCC. There was significant positive correlation between liver stiffness by fibroscan and tumour size (P<0.001), Child Pugh (P<0.001), Okuda classification (P<0.001), CLIP staging (P<0.001) and Tokyo classification (P<0.001) among HCC patients. Figures (3,4,5, 6,7) respectively. Badran et al., Afro-Egypt J Infect Endem Dis 2017; 7(3):
4 162 Table (1) : Demographic features of the studied patients HCC (N= 50) Age (years) Mean ± SD 53.5 ± 6.3 Range Gender Male Female Residence Rural Urban Occupation Farmer Non-farmer Smoking Yes No Non HCC (N= 50) 51.3 ± N % N % P-value HCV Ab HBs Ag Severity of liver disease Child-Pugh Classification Child A Child B Child C MELD Score Range Mean±SD 20.6± ±9.1 umeld Score Range Mean±SD 4.2± ±1.1 SD: standard deviation; HCC: hepatocellular carcinoma; HCV: hepatitis C virus; HBs Ag: Hepatitis B surface Antigen Badran et al., Afro-Egypt J Infect Endem Dis 2017; 7(3):
5 163 Table (2): Tumor related findings and characteristics of HCC in the studied patients HCC group N=50 N % Cirrhosis Splenomegaly Portal vein thrombosis 7 14 Number Single / 2 / multiple 26 / 8 / / 16 / 32 Site Rt lobe/ Lt lobe/both 27/5/18 54 /10 /36 Size 3cm / 3cm 18 / / 64 Lymph node Tumor staging Okuda staging 5 10 I / II / III CLIP staging 8 / 19 / / 38 / 46 I / II / III VISUM staging 5 / 31 / / 62 / 28 I / II / III Tokyo staging 29 / 8 / / 16 / 26 Early ( 5) / Advanced ( 5) AFP (ng/ml) level 21 / / 58 Range Mean ± SD 627.6± 1286 AFP: Alphafetoprotein; CLIP: Cancer of the liver Italian program; HCC: hepatocellular carcinoma; VISUM: Vienna survival model. Table (3) : Fibroscan results of the studied patients HCC Non HCC N=50 N=50 P Range Mean ± SD Range Mean ± SD 1-Stiffness ± ± * 2-IQR ± ± * 3- Success rate ± ± * = significant IQR = Inter Quartile Range Badran et al., Afro-Egypt J Infect Endem Dis 2017; 7(3):
6 Sensitivity HCC Non HCC 20 0 Stiffness IQR Success Figure (1) : Fibroscan results of the studied patients Table (4) : ROC curve analysis of Stiffness in prediction of hepatocellular carcinoma Cutoff point 30.4 kpa Sensitivity (%) 72.0% Specificity (%) 84.0% PPV (%) 81.82% NPV (%) 75.0% AUC Correctly classified 78.0% PPV=Positive predictive value NPV=Negative predictive value AUC = Area Under the Curve Specificity Area under ROC curve = Figure (2) : ROC curve analysis of Stiffness in prediction of hepatocellular carcinoma Badran et al., Afro-Egypt J Infect Endem Dis 2017; 7(3):
7 Child classification Size of tumour (cm) 165 Table (5) : Stratum Specific Likelihood Ratio (SSLR) for HCC risk by measurement of liver stiffness Strata Non HCC (No.=50) HCC (No.=50) SSLR No. % No. % < r= 0.85 P< Stiffness Figure (3) : Correlation between the size of the tumor and liver stiffness 3 2 p=0.56 P< Stiffness Figure (4) : Correlation between Child score and liver stiffness Badran et al., Afro-Egypt J Infect Endem Dis 2017; 7(3):
8 Clip staging Okuda classification p=0.80 P< Stiffness Figure (5) : Correlation between Okuda classification and liver stiffness 3 2 p=0.79 P< Stiffness Figure (6) : Correlation between CLIP staging and liver stiffness Badran et al., Afro-Egypt J Infect Endem Dis 2017; 7(3):
9 Tokyo classification p=0.72 P< Stiffness Figure (7) : Correlation between Tokyo classification and liver stiffness DISCUSSION In this study, liver stiffness and Inter Quartile Range (IQR) measured by Fibroscan were significantly higher in HCC group. This goes in agreement with Mi Sung et al. [11] who stated that the presence of HCC is associated with higher values of fibroscan. In this study, when using ROC curve of fibroscan as a marker of HCC diagnosis, the cutoff value for HCC was 30.4 kpa with sensitivity of 72%, specificity of 84%, positive predictive value of 81.82% and negative predictive value of 75%. This was near the results of Foucher et al. [12], who stated that the cutoff values for HCC which was 53.7kPa. Also in this study, there was a significant positive correlation between the liver stiffness and the presence of HCC. Also, prediction of occurrence of HCC by fibroscan may be of useful value. SSLR for HCC presence by liver stiffness was in <25 kpa, in 25.1 to 30kPa, 1.00 in 30.1 to 35 kpa, in 35.1 to 40 kpa and in >40 kpa. These results were in agreement with Masuzaki et al. [4] and Yosry et al. [13] who stated that there is association between LSM and the risk of HCC development in chronic HCV patients. SSLR for HCC presence by liver stiffness was in <10 kpa, in 10.1 to 15 kpa, in 15.1 to 25 kpa, and 15 in >25 kpa. This study showed that there was a significant positive correlation between results of fibroscan and Child- Paugh classification. It was found that fibroscan stiffness was higher in patients with Child B&C than patients with Child A classification. This correlation was not discussed by researchers however, Pesce et al. [14] stated that patients with Child B&C had the highest value measured by fibroscan. Also, it was found that there was no correlation between MELD and umeld Score and the stiffness measured by fibroscan. These results were different than those noted by Pesce et al. [14] who found that there was positive correlation between MELD and umeld score and fibroscan results. They found that MELD score results more than 10 had stiffness about Kpa while MELD score less than 10 had stiffness about Kpa. In this study, it was found that there was no correlation between tumour number and stiffness measured by fibroscan which is not discussed by researchers till now. Also there was significant positive correlation between the size of the tumour and stiffness measured by fibroscan. The bigger the size of the tumor, the higher the stiffness. These results were in agreement with Liana et al. [15] who stated that LSM was significantly higher in patients with HCC with nodules >50 mm (58.3±18.4 kpa vs32.5±14.3 kpa). Also, the current study showed that there was a significant positive correlation between Okuda classification, CLIP staging with the stiffness measured by fibroscan. The more advanced liver disease (according to each classification), the higher stiffness of fibroscan. This correlation is not discussed by researchers till now. This study found that there was no correlation between VISUM and stiffness measured by fibroscan which is not discussed by researchers till now. Also, this study showed that there was a significant positive correlation between Tokyo classification and stiffness measured by fibroscan which is not discussed by researchers till now. Badran et al., Afro-Egypt J Infect Endem Dis 2017; 7(3):
10 168 CONCLUSION According to this study, fibroscan has an important role in early detection of HCC in cirrhotic patients with cut off 30.4 Kpa. Cirrhotic patients with liver stiffness 30 kpa are most likely to have HCC. Cirrhotic patients with liver stiffness 25 kpa need close follow up as they are at high risk to develop HCC. Conflict of interest : The author declared that he has no competing interests or conflict of interest. ACKNOWLEDGEMENT: I would like to express my deepest gratefulness and greatest thanks to all who helped me in this work to be expressed in an acceptable fashion. I cannot find words to express the depth of my gratitude and respect to Professor. Hossam Amin Bioumy, professor of Hepatology, Gastroenterology and Infectious Diseases, Faculty of Medicine, University of Benha. Also Professor Seham Sief, Professor of Internal Medicine (Gastroenterology and Hepatology), Faculty of medicine, Mansoura University. She was my instructor of fibroscan. I also wish to extend my thanks to Prof. Naglaa El-Toukhy, Assistant Professor of Hepatology, Gastroenterology and Infectious Diseases, Faculty of Medicine, University of Benha, for her kind guidance and fruitful advice to complete this thesis. REFERENCES 1- Forner A, Reig M, Varela M, Burrel M, Feliu J, Briceño J, et al. Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH. Med Clin 2016; 146(11), 511-e1. 2- Elbaz, T, El Kassas, M, Esmat G. Management of Hepatocellular Carcinoma: Updated Review. J Cancer Therapy 2013; 4, Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: Masuzaki R, Tateishi R, Yoshida H, Goto E., Sato T, Ohki T et al. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography, Hepatology 2009; 49: Saar B, Kellner-Weldon F. Radiological diagnosis of HCC. Liver Int. 2008; 28(2): Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985; 56: Capuano G, Daniele B, Gaeta G, Gallo C, Perrone F. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998; 28(3): Schöniger-Hekele M, Müller C, Kutilek M, Oesterreicher C, Ferenci P, Gangl A. Hepatocellular carcinoma in central Europe: prognostic features and survival. Gut 2001; 48: Tateishi R, Yoshida H, Shiina S, Imamura H, Hasegawa K, Teratani T et al. Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients. Gut 2005; 54: Bruix J, Sherman M. Management of hepatocellular carcinoma. An update Hepatology 2011; 53(3): Park MS, Han KH, Kim S U., Non-invasive prediction of development of hepatocellular carcinoma using transient elastography in patients with chronic liver disease. Expert Review of Gastroenterology & Hepatology Vol. 8, Iss. 5, Foucher J, Castéra L, Bernard PH, Adhoute X, Laharie D, Bertet J et al. Prevalence and factors associated with failure of liver stiffness measurement using FibroScan in a prospective study of 2114 examinations. Eur J Gastroenterol Hepatol. 2006; 18(4): Yosry A, Fouad R, Hafez H A, Al Arab M E, Gohar M, Esmat G. Transient Elastography can Predict the Risk of Hepatocellular Carcinoma in Egyptian Patients with Chronic Hepatitis C. Journal of Gastroenterology and Hepatology Research 2013, 2(7), Pesce A, Scilletta, R., Branca, A, Nigro, L, Montineri A, Larocca L et al. Does transient elastography have a role in decision making in hepatocellular carcinoma? HPB 2012, 14: Gheorghe L, Iacob S, Ghidu C, Iacob R, Cerban R, Simionov I et al. Liver Stiffness Value Assessed by Transient Elastography Correlates With Nodule Size in Patients With Hepatocellular Carcinoma. Gastroenterology 2012; 142(5):S-979-S-980. Badran et al., Afro-Egypt J Infect Endem Dis 2017; 7(3):
Gamal F. El Naggar (1), Eman A. Alzamarany (2)
Diagnostic value of Protein Induced by Vitamin K Absence or Antagonist - II (PIVIKA II) in patients with hepatocellular carcinoma (HCC): Comparison with alpha fetoprotein Gamal F. El Naggar (1), Eman A.
More informationJournal of. Transient Elastography can Predict the Risk of Hepatocellular Carcinoma in Egyptian Patients with Chronic Hepatitis C
Journal of Gastroenterology and Hepatology Research Online Submissions: http://www.ghrnet.org/index./joghr/ doi:10.6051/j.issn.2224-3992.2013.02.300 Journal of GHR 2013 July 21 2(7): 687-691 ISSN 2224-3992
More informationSurveillance for Hepatocellular Carcinoma
Surveillance for Hepatocellular Carcinoma Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded on April
More informationNon-Invasive Testing for Liver Fibrosis
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Non-Invasive Testing for Liver Fibrosis John Scott, MD, MSc Associate Professor, University of Washington Associate Clinic Director, Hep/Liver Clinic, Harborview
More informationThe role of ARFI and APRI in diagnosis of liver fibrosis on patients with common chronic liver diseases
RESEARCH ARTICLE The role of ARFI and APRI in diagnosis of liver fibrosis on patients with common chronic liver diseases Objective: This study aimed to investigate the value of liver fibrosis assessment
More informationLiver resection for HCC
8 th LIVER INTEREST GROUP Annual Meeting Cape Town 2017 Liver resection for HCC Jose Ramos University of the Witwatersrand Donald Gordon Medical Centre The liver is almost unique in that treatment of the
More informationTransient elastography the state of the art
Transient elastography the state of the art Laurent CASTERA, MD PhD Department of Hepatology, Hôpital Beaujon, Clichy Université Paris-7, France White Nights of Hepatology, St Petersburg, Russia, june
More informationThe role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis
The role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis Objectives: Liver biopsy is the gold standard for diagnosing the extent of fibrosis in NAFLD/NASH;
More informationHepatocellular Carcinoma. Markus Heim Basel
Hepatocellular Carcinoma Markus Heim Basel Outline 1. Epidemiology 2. Surveillance 3. (Diagnosis) 4. Staging 5. Treatment Epidemiology of HCC Worldwide, liver cancer is the sixth most common cancer (749
More information간암의다양한병기분류법 : 현재사용중인병기분류를중심으로. Kim, Beom Kyung
간암의다양한병기분류법 : 현재사용중인병기분류를중심으로 Kim, Beom Kyung Importance of staging system 환자의예후예측 적절한치료방법적용 ( 수술, 방사선, 항암..) 의료진간의 tumor burden 에대한적절한의사소통 향후연구및 clinical trial 시연구집단의성격에대한객관적기준제시 Requisites for good staging
More informationLong-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance
Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance Gi-Ae Kim, Han Chu Lee *, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim,
More informationJournal of the Egyptian Society of Parasitology, Vol.46, No.1, April 2016 J. Egypt. Soc. Parasitol. (JESP), 46(1), 2016:
Journal of the Egyptian Society of Parasitology, Vol.46, No.1, April 2016 J. Egypt. Soc. Parasitol. (JESP), 46(1), 2016: 125-130 SERUM MARKERS FOR ASSESSING LIVER FIBROSIS IN EGYPTIAN PA- TIENTS WITH CHRONIC
More informationClinical Staging for Hepatocellular Carcinoma: Eastern Perspectives. Osamu Yokosuka, M.D. Graduate School of Medicine, Chiba University, Chiba, Japan
Clinical Staging for Hepatocellular Carcinoma: Eastern Perspectives Osamu Yokosuka, M.D. Graduate School of Medicine, Chiba University, Chiba, Japan Why is staging system important? Cancer stage can be
More informationNON INVASIVE ASSESSMENT OF LIVER FIBROSIS : FIBROSCAN
NON INVASIVE ASSESSMENT OF LIVER FIBROSIS : FIBROSCAN M. Beaugrand Service d Hépatologied Hopital J. Verdier BONDY 93143 et Université Paris XIII MAINZ 21.09.2008 ASSESSMENT OF FIBROSIS : WHY? Management
More informationModule 1 Introduction of hepatitis
Module 1 Introduction of hepatitis 1 Training Objectives At the end of the module, trainees will be able to ; Demonstrate improved knowledge of the global epidemiology of the viral hepatitis Understand
More informationReal-time elastography as a noninvasive assessment of liver fibrosis in chronic hepatitis C Egyptian patients: a prospective study
ORIGINAL ARTICLE Annals of Gastroenterology (2016) 29, 1-5 Real-time elastography as a noninvasive assessment of liver fibrosis in chronic hepatitis C Egyptian patients: a prospective study Lamiaa Mobarak
More informationABSTRACT INTRODUCTION. *Diana Feier 1, *Monica Lupsor Platon 1,2, Horia Stefanescu 1,3, Radu Badea 1,2
Transient Elastography for the Detection of Hepatocellular Carcinoma in Viral C Liver Cirrhosis. Is there something else than Increased Liver Stiffness? *Diana Feier 1, *Monica Lupsor Platon 1,2, Horia
More informationImproved Hepatic Fibrosis Grading Using Point Shear Wave Elastography and Machine Learning
Improved Hepatic Fibrosis Grading Using Point Shear Wave Elastography and Machine Learning Presenter: Hersh Sagreiya 1, M.D. Authors: Alireza Akhbardeh 1, Ph.D., Isabelle Durot 1, M.D., Carlo Filice 2,
More informationEvaluation of liver and spleen stiffness using a ultrasound guided method: Accuracy of ARFI(R) measurements in liver disease patients
Evaluation of liver and spleen stiffness using a ultrasound guided method: Accuracy of ARFI(R) measurements in liver disease patients Poster No.: C-3242 Congress: ECR 2010 Type: Topic: Authors: Keywords:
More informationLearning Objectives. After attending this presentation, participants will be able to:
Learning Objectives After attending this presentation, participants will be able to: Describe HCV in 2015 Describe how to diagnose advanced liver disease and cirrhosis Identify the clinical presentation
More informationWhen to Treat: Staging Liver Disease David L. Thomas, MD, MPH
When to Treat: Staging Liver Disease David L. Thomas, MD, MPH Professor of Medicine Johns Hopkins School of Medicine Disclosures Received royalties from UpToDate, Inc. Staging refers to the assessment
More informationTransient elastography in chronic viral liver diseases
4 th AISF POST-MEETING COURSE Roma, 26 Febbraio 2011 Transient elastography in chronic viral liver diseases CRISTINA RIGAMONTI, M.D., Ph.D. Transient elastography (TE): a rapid, non-invasive technique
More informationOriginal Article. Comparison of 7 staging systems in north Indian cohort of hepatocellular carcinoma
Tropical Gastroenterology 2010;31(4):271 278 Original Article Comparison of 7 staging systems in north Indian cohort of hepatocellular carcinoma *Sanjay Sarma 1, *Balkrishan Sharma 1, Yogesh Kumar Chawla
More informationSurveillance for HCC Who, how Diagnosis of HCC Surveillance for HCC in Practice
Surveillance for Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline
More informationHow to apply HCC prediction models to practice?
How to apply HCC prediction models to practice? Department of Internal Medicine, Keimyung University School of Medicine Woo Jin Chung HCC prediction models 독특하게간세포암환자들의생존은암의진행상태뿐아니라기저간기능의중증정도에영향을받는특성이있다.
More informationHepatocellular Carcinoma: Epidemiology and Screening
Hepatocellular Carcinoma: Epidemiology and Screening W. Ray Kim, MD Professor and Chief Gastroenterology and Hepatology Stanford University School of Medicine Case A 67 year old Filipino-American woman
More informationJPGN Journal of Pediatric Gastroenterology and Nutrition Publish Ahead of Print
JPGN Journal of Pediatric Gastroenterology and Nutrition Publish Ahead of Print DOI : 10.1097/MPG.0000000000000489 Points to be considered when Applying FibroScan S Probe for Children with Biliary Atresia
More informationEvaluation of liver and spleen stiffness using a ultrasound guided method: Accuracy of ARFI(R) measurements in liver disease patients
Evaluation of liver and spleen stiffness using a ultrasound guided method: Accuracy of ARFI(R) measurements in liver disease patients Poster No.: C-3242 Congress: ECR 2010 Type: Topic: Authors: Keywords:
More informationLiver Biopsy and FibroScan to Detect Early Histopathological Changes in Chronic HBV Patients Not Candidate for Treatment
Original Article Elmer Press Liver Biopsy and FibroScan to Detect Early Histopathological Changes in Chronic HBV Patients Not Candidate for Treatment Sahar Maklad a, Gamal Esmat b, Ehsan Hassan c, Mohamed
More informationAre we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting?
Rajani Sharma, PGY1 Geriatrics CRC Project, 12/19/13 Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting? A. Study Purpose and Rationale Hepatocellular carcinoma
More informationOriginal papers Med Ultrason 2013, Vol. 15, no. 2, Ioan Sporea, Iulia Raţiu, Simona Bota, Roxana Şirli, Ana Jurchiş
Original papers Med Ultrason 2013, Vol. 15, no. 2, 111-115 DOI: 10.11152/mu.2013.2066.152.is1ir2 Are different cut-off values of liver stiffness assessed by Transient Elastography according to the etiology
More informationLiver stiffness predicts liver related events and mortality in HIV/HCV coinfected patients
Liver stiffness predicts liver related events and mortality in HIV/HCV coinfected patients José Vicente Fernández-Montero, Pablo Barreiro, Eugenia Vispo, Pablo Labarga, Francisco Blanco, Fernanda Rick,
More informationNational Horizon Scanning Centre. Enhanced Liver Fibrosis Test (ELF) for evaluating liver fibrosis. June 2008
Enhanced Liver Fibrosis Test (ELF) for evaluating liver fibrosis June 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationNoninvasive Diagnosis and Staging of Liver Disease. Naveen Gara, MD
Noninvasive Diagnosis and Staging of Liver Disease Naveen Gara, MD Outline Brief overview of the anatomy of liver Liver-related lab tests Chronic liver disease progression Estimation of liver fibrosis
More informationNoninvasive Assessment of Liver Fibrosis in Egyptian Children with Chronic Liver Diseases.
Curr Pediatr Res 2016; 20 (1&2): 57-63 ISSN 0971-9032 www.currentpediatrics.com Noninvasive Assessment of Liver Fibrosis in Egyptian Children with Chronic Liver Diseases. Tawhida Abdel Ghaffar 1, Azza
More informationResearch Article Accurate Prediction of Advanced Liver Fibrosis Using the Decision Tree Learning Algorithm in Chronic Hepatitis C Egyptian Patients
Gastroenterology Research and Practice Volume 2016, Article ID 2636390, 7 pages http://dx.doi.org/10.1155/2016/2636390 Research Article Accurate Prediction of Advanced Liver Fibrosis Using the Decision
More informationRESEARCH ARTICLE. Real Life Treatment of Hepatocellular Carcinoma: Impact of Deviation from Guidelines for Recommended Therapy
DOI:http://dx.doi.org/10.7314/APJCP.2015.16.16.6929 Real-Life HCC Treatment - Influence on Outcome of Deviation from Therapy Guidelines RESEARCH ARTICLE Real Life Treatment of Hepatocellular Carcinoma:
More informationManagement of Liver Diseases: A Nonhepatologist s Viewpoint
Management of Liver Diseases: A Nonhepatologist s Viewpoint Arthur Y. Kim, MD Associate Professor of Medicine Harvard Medical School Director, Viral Hepatitis Clinic Massachusetts General Hospital Boston,
More informationLife Science Journal 2014;11(9s)
Evaluation of the Effectiveness of Serum Golgi Protein 73 as Tumor Marker for Diagnosis of Hepatocellular Carcinoma Sherif Monier Mohamed (1), Hany Aly Hussein (1), Mostafa Hamed Abd Elaleem (2) and Yasmin
More informationHepatology for the Nonhepatologist
Hepatology for the Nonhepatologist Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Cincinnati, Ohio Learning
More informationHepatocellular Carcinoma: Diagnosis and Management
Hepatocellular Carcinoma: Diagnosis and Management Nizar A. Mukhtar, MD Co-director, SMC Liver Tumor Board April 30, 2016 1 Objectives Review screening/surveillance guidelines Discuss diagnostic algorithm
More informationPrediction of Hepatocellular Carcinoma Incidence Risk by Ultrasound Elastography
2235-1795/14/0031-0001$39.50/0 1 Editorial Prediction of Hepatocellular Carcinoma Incidence Risk by Ultrasound Elastography Prof. M. Kudo Editor Liver Cancer In patients with chronic hepatitis and continuous
More informationOriginal article On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients
Antiviral Therapy 2011; 16:165 172 (doi: 10.3851/IMP1726) Original article On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients Grace Lai-Hung Wong 1,2,
More informationDIAGNOSIS OF CIRRHOSIS BY TRANSIENT ELASTOGRAPHY (FIBROSCAN ): A PROSPECTIVE STUDY.
Gut Online First, published on July 14, 2005 as 10.1136/gut.2005.069153 DIAGNOSIS OF CIRRHOSIS BY TRANSIENT ELASTOGRAPHY (FIBROSCAN ): A PROSPECTIVE STUDY. Juliette Foucher (1), Elise Chanteloup (1), Julien
More informationScreening for HCCwho,
Screening for HCCwho, how and how often? Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital HCC Global Epidemiology
More informationAssessment of Liver Function: Implications for HCC Treatment
Assessment of Liver Function: Implications for HCC Treatment A/P Dan Yock Young MBBS, PhD, MRCP, MMed. FAMS Chair, University Medicine Cluster. NUHS Head, Department of Medicine, National University of
More informationScreening for Portal Hypertension in Cirrhosis
Screening for Portal Hypertension in Cirrhosis MASSIMO PINZANI, MD, PhD, FRCP Sheila Sherlock Chair of Hepatology UCL Institute for Liver and Digestive Health Royal Free Hospital, London, UK m.pinzani@ucl.ac.uk
More informationMR Elastography of Liver
MR Elastography of Liver Sudhakar K. Venkatesh, MD, FRCR Professor of Radiology Mayo Clinic College of Medicine Consultant, Abdominal Division Radiology, Mayo Clinic Rochester, MN, USA 19 th May 2018 2018
More informationRESEARCH ARTICLE. Validation of The Hong Kong Liver Cancer Staging System in Patients with Hepatocellular Carcinoma after Curative Intent Treatment
DOI:10.22034/APJCP.2017.18.6.1697 RESEARCH ARTICLE Validation of The Hong Kong Liver Cancer Staging System in Patients with Hepatocellular Carcinoma after Curative Intent Treatment Alan Chuncharunee 1,
More informationMeasuring levels of osteopontin as potential biomarker for hepatocellular carcinoma in Syrian patients
Gastroenterology and Hepatology From Bed to Bench. 2017 RIGLD, Research Institute for Gastroenterology and Liver Diseases ORIGINAL ARTICLE Measuring levels of osteopontin as potential biomarker for hepatocellular
More informationOriginal Article. Six Month Follow-up of Liver Stiffness Measurement in Untreated Chronic Hepatitis C With or Without HIV Co-infection
Original Article Phrommee N, et al. 15 Six Month Follow-up of Liver Stiffness Measurement in Untreated Chronic Hepatitis C With or Without HIV Co-infection Phrommee N Leerapun A Pisespongsa P Chitapanarux
More informationAssessment of Liver Stiffness by Transient Elastography in Diabetics with Fatty Liver A Single Center Cross Sectional observational Study
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 16, Issue 6 Ver. IV (June. 2017), PP 49-53 www.iosrjournals.org Assessment of Liver Stiffness by Transient
More informationPROPOSTA DI UN NUOVO ALGORIMO PER LA DIAGNOSI ECOGRAFICA DELLE MALATTIE CRONICHE DEL FEGATO
PROPOSTA DI UN NUOVO ALGORIMO PER LA DIAGNOSI ECOGRAFICA DELLE MALATTIE CRONICHE DEL FEGATO A. Giorgio Direttore del servizio di Ecografia Interventistica Istituto Clinico S.Rita -IRCCS -Atripalda (Avellino)
More informationNomograms to Predict the Disease-free Survival and Overall Survival after Radiofrequency Ablation for Hepatocellular Carcinoma
doi: 10.2169/internalmedicine.9064-17 Intern Med Advance Publication http://internmed.jp ORIGINAL ARTICLE Nomograms to Predict the Disease-free Survival and Overall Survival after Radiofrequency Ablation
More informationLiver Stiffness in Patients After the Fontan Procedure is Correlated with Age at Time of Surgery and Time since Surgery
Liver Stiffness in Patients After the Fontan Procedure is Correlated with Age at Time of Surgery and Time since Surgery Yuki Cho 1), Daisuke Tokuhara 1), Yuki Kawasaki 2), Eiji Ehara 2), Yosuke Murakami
More informationHepatocellular carcinoma in Central Europe: prognostic features and survival
Gut 2001;48:103 109 103 Universitätsklinik für Innere Medizin IV, Klinische Abteilung Gastroenterologie und Hepatologie, University of Vienna, Austria M Schöniger-Hekele C Müller M Kutilek C Oesterreicher
More informationLiver transplantation: Hepatocellular carcinoma
Liver transplantation: Hepatocellular carcinoma Alejandro Forner BCLC Group. Liver Unit. Hospital Clínic. University of Barcelona 18 de marzo 2015 3r Curso Práctico de Transplante de Órganos Sólidos Barcelona
More information9th Paris Hepatitis Conference
9th Paris Hepatitis Conference Paris, 12 January 2016 Treatment of hepatocellular carcinoma: beyond international guidelines Massimo Colombo Chairman Department of Liver, Kidney, Lung and Bone Marrow Units
More informationOriginal Article. Key Words: liver stiffness, US score, ultrasound imaging, liver cirrhosis. Introduction
27 2017; 64: 27-34 M. Endo et al. Original Article Ultrasound evaluation of liver stiffness: accuracy of ultrasound imaging for the prediction of liver cirrhosis as evaluated using a liver stiffness measurement
More informationHepatocytes produce. Proteins Clotting factors Hormones. Bile Flow
R.J.Bailey MD Hepatocytes produce Proteins Clotting factors Hormones Bile Flow Trouble.. for the liver! Trouble for the Liver Liver Gall Bladder Common Alcohol Hep C Fatty Liver Cancer Drugs Viruses Uncommon
More informationNon-Invasive Assessment of Liver Fibrosis. Patricia Slev, PhD University of Utah Department of Pathology
Non-Invasive Assessment of Liver Fibrosis Patricia Slev, PhD University of Utah Department of Pathology Disclosure Patricia Slev has no relevant financial relationships to disclose. 2 Chronic Liver Disease
More informationKing Abdul-Aziz University Hospital (KAUH) is a tertiary
Modelling Factors Causing Mortality in Oesophageal Varices Patients in King Abdul Aziz University Hospital Sami Bahlas Abstract Objectives: The objective of this study is to reach a model defining factors
More informationPaul Martin MD FACG. University of Miami
Paul Martin MD FACG University of Miami 1 Liver cirrhosis of any cause Chronic C o c hepatitis epat t s B Risk increases with Male gender Age Diabetes Smoking ~5% increase in HCV-related HCC between 1991-28
More informationNew York State HCV Provider Webinar Series
New York State HCV Provider Webinar Series Overview of Fibrosis-Staging, Child s Pugh, MELD Scores Paul J Gaglio, MD, FACP, AGAF, FAASLD Director: Hepatology Outreach Professor of Medicine (in Surgery)
More informationSIRTEX Lunch Symposium, Cebu, 23 Nov Dr. Stephen L. Chan Department of Clinical Oncology The Chinese University of Hong Kong
SIRTEX Lunch Symposium, Cebu, 23 Nov 2013 Dr. Stephen L. Chan Department of Clinical Oncology The Chinese University of Hong Kong I will not talk on Mechanism of SIRT Data on efficacy of SIRT Epidemiology
More informationiu22 Liver Shear Wave ElastPQ
iu22 Liver Shear Wave ElastPQ Clinical Case Study Lucy Wang Clinical Application Specialist ASEAN Case Study: History: 58-year-old male patient, hepatitis B virus (HBV) carrier, with non clinical symptoms
More informationHepatitis Alert: Management of Patients With HCV Who Have Achieved SVR
Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR This program is supported by educational grants from AbbVie, Gilead Sciences, and Merck About These Slides Please feel free to use,
More informationClinical Policy Title: Noninvasive assessment of hepatic fibrosis
Clinical Policy Title: Noninvasive assessment of hepatic fibrosis Clinical Policy Number: 08.01.03 Effective Date: Oct. 1, 2014 Initial Review Date: June 18, 2014 Most Recent Review Date: August 17, 2017
More information*APHP: Hôpital Beaujon Professor P Bedossa, Dr F Degos, Professor P Marcellin, Professor
APPENDIX 1 LIST OF COINVESTIGATORS *APHP: Hôpital Beaujon Professor P Bedossa, Dr F Degos, Professor P Marcellin, Professor M Vidaud; Hôpital Cochin-Necker: Professor S Pol, Professor Ph Sogni, Professor
More informationCIRROSI E IPERTENSIONE PORTALE NELLA DONNA
Cagliari, 16 settembre 2017 CIRROSI E IPERTENSIONE PORTALE NELLA DONNA Vincenza Calvaruso, MD, PhD Ricercatore di Gastroenterologia Gastroenterologia & Epatologia, Di.Bi.M.I.S. Università degli Studi di
More information5/2/2016. Arthur Y. Kim, MD Assistant Professor of Medicine Harvard Medical School Massachusetts General Hospital Boston, Massachusetts
Management of Liver Diseases (A Nonhepatologist s Viewpoint) Arthur Y. Kim, MD Assistant Professor of Medicine Harvard Medical School Massachusetts General Hospital Boston, Massachusetts FINAL: 04/11/2016
More informationResearch Elastography: Liver
Research Elastography: Liver Giovanna Ferraioli EFSUMB Ultrasound Learning Center Ultrasound Unit - Infectious Diseases Dept. Fondazione IRCCS Policlinico S. Matteo Medical School University of Pavia,
More informationTreatment of HCC in real life-chinese perspective
Treatment of HCC in real life-chinese perspective George Lau MBBS (HK), MRCP(UK), FHKCP, FHKAM (GI), MD(HK), FRCP (Edin, Lond), FAASLD (US) Chairman Humanity and Health Medical Group, Hong Kong SAR, CHINA
More informationWho to Treat? Consider biopsy Treat. > 2 ULN Treat Treat Treat Treat CIRRHOTIC PATIENTS Compensated Treat HBV DNA detectable treat
Who to Treat? Parameter AASLD US Algorithm EASL APASL HBV DNA CRITERIA HBeAg+ >, IU/mL > 2, IU/mL > 2, IU/mL >, IU/mL HBeAg- > 2, IU/mL > 2, IU/mL > 2, IU/mL > 2, IU/mL ALT CRITERIA PNALT 1-2 ULN Monitor
More informationHEP DART 2017, Kona, Hawaii
HEP DART 2017, Kona, Hawaii Rong Yu 1, Ke Xu 1, Jing Li 1, Tong Sun 1, Shengjiang Zhang 2, Jinhua Shao 2, Jin Sun 2, Qiong He 3, Jianwen Luo 3, Cheng Wang 4, Yudong Wang 4, Jing Chen 4, Vanessa Wu 4, George
More informationHepatocellular Carcinoma (HCC)
Title Slide Hepatocellular Carcinoma (HCC) Professor Muhammad Umar MBBS, MCPS, FCPS (PAK), FACG (USA), FRCP (L), FRCP (G), ASGE-M(USA), AGAF (USA) Chair & Professor of Medicine Rawalpindi Medical College
More informationManagement of Hepatitis C in Primary Care BABAFEMI ONABANJO, MD & BEN ALFRED, FNP UMASS FAMILY HEALTH CENTER WORCESTER
Management of Hepatitis C in Primary Care BABAFEMI ONABANJO, MD & BEN ALFRED, FNP UMASS FAMILY HEALTH CENTER WORCESTER Objective Epidemiology Screening criteria Appropriate work up Treatment Guidelines
More informationHepatology For The Nonhepatologist
Hepatology For The Nonhepatologist Andrew Aronsohn, MD Associate Professor of Medicine University of Chicago Chicago, Illinois Learning Objectives After attending this presentation, learners will be able
More informationA SIMPLE MULTI-LINEAR REGRESSION MODEL FOR PREDICTING FIBROSIS SCORES IN CHRONIC EGYPTIAN HEPATITIS C VIRUS PATIENTS
International Journal of Bio-Technology and Research (IJBTR) ISSN(P): 2249-6858; ISSN(E): 2249-796X Vol. 4, Issue 3, Jun 2014, 37-46 TJPRC Pvt. Ltd. A SIMPLE MULTI-LINEAR REGRESSION MODEL FOR PREDICTING
More informationLiver Disease Assessment Among PWID: The Role of Transient Elastography
Liver Disease Assessment Among PWID: The Role of Transient Elastography Peer Brehm Christensen, Professor Department of Infectious Diseases Odense University Hospital Denmark Peer.christensen@dadlnet.dk
More informationCases: Treatment of Hepatitis C in Patients with Cirrhosis and Advanced Liver Disease
Slide 1 of 20 Cases: Treatment of Hepatitis C in Patients with Cirrhosis and Advanced Liver Disease Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University
More informationInvasive. Sampling error. Interobserver variability. Nondynamic evaluation of
How to assess liver fibrosis Serum markers or FibroScan vs. liver biopsy? Laurent CASTERA & Pierre BEDOSSA Hôpital Beaujon, AP-HP, Clichy Université Paris-VII France 4 th Paris Hepatitis Conference, Paris,
More informationNon-invasive diagnosis of hepatitis B virus-related cirrhosis
Online Submissions: http://www.wjgnet.com/esps/ bpgoffice@wjgnet.com doi:10.3748/wjg.v20.i2.445 World J Gastroenterol 2014 January 14; 20(2): 445-459 ISSN 1007-9327 (print) ISSN 2219-2840 (online) 2014
More informationComparison of transient elastography to Doppler indices in prediction of hepatitis C induced liver fibrosis and cirrhosis
The Egyptian Journal of Radiology and Nuclear Medicine (2011) 42, 111 117 Egyptian Society of Radiology and Nuclear Medicine The Egyptian Journal of Radiology and Nuclear Medicine www.elsevier.com/locate/ejrnm
More informationManagement of HepatoCellular Carcinoma
9th Symposium GIC St Louis - 2010 Management of HepatoCellular Carcinoma Overview Pierre A. Clavien, MD, PhD Department of Surgery University Hospital Zurich Zurich, Switzerland Hepatocellular carcinoma
More informationSelection Criteria and Insertion of SIRT into HCC Treatment Guidelines
Selection Criteria and Insertion of SIRT into HCC Treatment Guidelines 2 nd Asia Pacific Symposium on Liver- Directed Y-90 Microspheres Therapy 1st November 2014, Singapore Pierce Chow FRCSE PhD SIRT in
More informationInverse relationship between cirrhosis and massive tumours in hepatocellular carcinoma
DOI:10.1111/j.1477-2574.2012.00507.x HPB ORIGINAL ARTICLE Inverse relationship between cirrhosis and massive tumours in hepatocellular carcinoma Umut Sarpel 1, Diego Ayo 2, Iryna Lobach 3, Ruliang Xu 4
More informationXiao-Ling Chi, Mei-Jie Shi, Huan-Ming Xiao, Yu-Bao Xie, and Gao-Shu Cai. Correspondence should be addressed to Xiao-Ling Chi;
Evidence-Based Complementary and Alternative Medicine Volume 2016, Article ID 3743427, 6 pages http://dx.doi.org/10.1155/2016/3743427 Research Article The Score Model Containing Chinese Medicine Syndrome
More informationTransient elastography in chronic liver diseases of other etiologies
4 Post Meeting A.I.S.F. Unmet Clinical Needs in Hepatology: New and upcoming diagnostic tools" Transient elastography in chronic liver diseases of other etiologies Dr. Vincenza Calvaruso Gastroenterologia
More informationSteps in Assessing Fibrosis 4/30/2015. Overview of Liver Disease Associated With HCV
Overview of Liver Disease Associated With HCV Marion G. Peters, MD John V. Carbone, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco San Francisco,
More informationAlbumin-to-bilirubin score for assessing the in-hospital death in cirrhosis
Original Article Albumin-to-bilirubin score for assessing the in-hospital death in cirrhosis Lichun Shao 1 *, Bing Han 1 *, Shu An 2, Jiaxin Ma 1, Xiaozhong Guo 3, Fernando Gomes Romeiro 4, Andrea Mancuso
More informationAcoustic radiation force impulse elastography in distinguishing hepatic haemangiomata from metastases: preliminary observations
The British Journal of Radiology, 84 (2011), 939 943 SHORT COMMUNICATION Acoustic radiation force impulse elastography in distinguishing hepatic haemangiomata from metastases: preliminary observations
More informationFaculty Disclosure. Objectives. Cirrhosis Management for the Family Physician 18/11/2014
Cirrhosis Management for the Family Physician Mang Ma, MD, FRCP Professor University of Alberta Faculty: Mang Ma Faculty Disclosure Relationships with commercial interests: Advisory Board: Merck, Gilead
More informationHepatocellular carcinoma in Sri Lanka - where do we stand?
SCIENTIFIC ARTICLE Hepatocellular carcinoma in Sri Lanka - where do we stand? R.C. Siriwardana 1, C.A.H. Liyanage 1, M.B. Gunethileke 2 1. Specialist Gastrointestinal and Hepatobilliary Surgeon, Senior
More informationNature and Science 2018;16(11)
Study of Liver and Spleen Stiffness in Hepatitis C Related Cirrhotic Patients for Predicting Esophageal Varices in Egypt Salem Soliman Ahmed Salama 1, Abd-Almonem Mohamed Brak 1, Ibrahim Ali Ibrahim 2,
More informationWhite Nights of Hepatology 2016
White Nights of Hepatology 2016 Saint Petersburg, 3 June 2016 Long-term treatment of Chronic hepatitis B - a key to HCC prevention Massimo Colombo Chairman Department of Liver, Kidney, Lung and Bone Marrow
More informationMedical Review Approaches to the Diagnosis of Liver Fibrosis
Medical Review Approaches to the Diagnosis of Liver Fibrosis Hiroko Iijima Department of Hepatobiliary and Pancreatic Disease Ultrasound Imaging Center, Hyogo College of Medicine Hiroko Iijima Department
More informationTitle: The Baveno VI criteria for predicting esophageal varices: validation in real life practice
Title: The Baveno VI criteria for predicting esophageal varices: validation in real life practice Authors: Mafalda Sousa, Sónia Fernandes, Luísa Proença, Ana Paula Silva, Sónia Leite, Joana Silva, Ana
More informationThe Liver for the Nonhepatologist
The Liver for the Nonhepatologist Michael R. Charlton, MBBS, FRCP Hepatology Director and Medical Director of Liver Transplantation Intermountain Medical Center Salt Lake City, Utah FORMATTED: 05-14-15
More information